Marotta Asset Management Reduces Position in Astrazeneca Plc $AZN

Marotta Asset Management decreased its holdings in shares of Astrazeneca Plc (NYSE:AZN) by 50.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,959 shares of the company’s stock after selling 5,042 shares during the period. Marotta Asset Management’s holdings in Astrazeneca were worth $995,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of AZN. MV Capital Management Inc. bought a new position in Astrazeneca in the 4th quarter worth $26,000. Reflection Asset Management bought a new stake in Astrazeneca during the fourth quarter valued at about $31,000. Lloyd Advisory Services LLC. bought a new stake in Astrazeneca during the fourth quarter valued at about $35,000. Basepoint Wealth LLC bought a new stake in Astrazeneca during the fourth quarter valued at about $44,000. Finally, Acumen Wealth Advisors LLC purchased a new stake in Astrazeneca in the fourth quarter worth about $47,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Astrazeneca Trading Up 6.0%

Shares of AZN stock opened at $194.96 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. The stock has a fifty day simple moving average of $183.91 and a two-hundred day simple moving average of $187.76. The firm has a market capitalization of $302.36 billion, a PE ratio of 29.27, a PEG ratio of 1.49 and a beta of 0.24. Astrazeneca Plc has a 52-week low of $137.23 and a 52-week high of $212.71.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion for the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. On average, analysts predict that Astrazeneca Plc will post 10.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on AZN. Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. UBS Group reissued a “buy” rating on shares of Astrazeneca in a report on Friday, April 10th. The Goldman Sachs Group restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday. Finally, Bank of America reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday. Fourteen equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $205.33.

Astrazeneca News Roundup

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: AstraZeneca announced a strategic collaboration with Abbisko Therapeutics to advance a Phase I/II clinical trial of lumipodlin (ABSK043) combined with Tagrisso for non-small cell lung cancer, adding another pipeline development opportunity. Article Title
• Positive Sentiment: AZN’s cancer drug Enhertu won another EU approval for HER2-positive solid tumors, extending its commercial footprint and reinforcing investor confidence in the company’s oncology franchise. Article Title
• Positive Sentiment: Goldman Sachs and Bank of America both reaffirmed “buy” ratings on AstraZeneca, while Erste Group raised its FY2026 EPS estimate, signaling continued analyst confidence in earnings power. Article Title
• Positive Sentiment: Separate style-score coverage from Zacks highlighted AZN as both a strong value stock and a strong momentum stock, which may have supported buying interest. Article Title
• Neutral Sentiment: MarketBeat noted that AstraZeneca’s shares have recently traded below some valuation-based fair value estimates, suggesting the stock still screens as expensive despite the recent rally.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.